Tryptamine Therapeutics (ASX:TYP) Ending Cash Position : A$2.61 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Tryptamine Therapeutics Ending Cash Position?

Tryptamine Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 was A$2.61 Mil.

Tryptamine Therapeutics's quarterly Ending Cash Position declined from Dec. 2022 (A$1.69 Mil) to Jun. 2023 (A$1.64 Mil) but then increased from Jun. 2023 (A$1.64 Mil) to Dec. 2023 (A$2.61 Mil).

Tryptamine Therapeutics's annual Ending Cash Position declined from Jun. 2021 (A$12.72 Mil) to Jun. 2022 (A$4.85 Mil) and declined from Jun. 2022 (A$4.85 Mil) to Jun. 2023 (A$1.64 Mil).

Tryptamine Therapeutics Ending Cash Position Historical Data

The historical data trend for Tryptamine Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tryptamine Therapeutics Ending Cash Position Chart

Tryptamine Therapeutics Annual Data

Trend

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Ending Cash Position

Get a 7-Day Free Trial

4.42

1.74

12.72

4.85

1.64

Tryptamine Therapeutics Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Ending Cash Position	Get a 7-Day Free Trial						9.37	4.85	1.69	1.64	2.61

Tryptamine Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Tryptamine Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	4.847	+	-3.204
	=	1.64

Tryptamine Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.642	+	0.965
	=	2.61

Tryptamine Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Tryptamine Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Tryptamine Therapeutics (ASX:TYP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tryptamine Therapeutics Ltd (ASX:TYP) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

697 Burke Road, Suite 201, Camberwell, VIC, AUS, 3124

Website

https://www.exopharm.com

Exopharm Ltd is a biopharmaceutical company that engages in the development of regenerative medicine in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. The company operates in one segment namely the research and development of biopharmaceutical drugs. Revenue is generated from Australia.

Tryptamine Therapeutics (ASX:TYP) Headlines

No Headlines